All In Biotech

Free tool

FAERS Monitor: Zylet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 050804 or its brand name (Zylet, Loteprednol Etabonate, Tobramycin). Reports on generic versions are filed under their own applications.

Reports

400

Serious

116

29% of reports

Hospitalization

40

Death reported

9

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain49
  • ocular hyperaemia48
  • eye irritation47
  • drug ineffective41
  • vision blurred31
  • headache30
  • lacrimation increased28
  • eye pruritus21
  • chronic kidney disease20
  • eye swelling19
  • condition aggravated18
  • drug hypersensitivity18
  • hypersensitivity18
  • visual impairment16
  • renal failure13

Reports by year received

View as table
YearReports
200724
200818
20094
201026
201124
201220
20137
20148
201520
201624
201732
201839
201956
202022
202122
202226
20239
20246
202510
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,759 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ocular hyperaemiaSignal4853.240.82,411
lacrimation increasedSignal2848.834.11,263
eye painSignal4945.735.22,102
eye irritationSignal4743.032.81,889
eye pruritusSignal2132.921.7618
eye swellingSignal1926.917.3448
chronic kidney diseaseSignal2013.89.0226
vision blurredSignal3111.98.5300
visual impairmentSignal166.84.274
renal failureSignal135.13.040
hypersensitivitySignal185.13.256
drug hypersensitivitySignal184.93.152
condition aggravatedSignal183.12.024
headacheSignal302.51.827
drug ineffective411.61.210

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.